Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

Summary

The objective of the study is to assess efficacy and safety of SHR4640 in subjects with hyperuricemia.

Timeline

Start

2017-07-20

Primary completion

2018-07-20

Completion

2018-07-20

Outcome

Met primary endpoint

paper significantly higher than the placebo group (0%; P < 0.05 for 5 mg and 10 mg SHR4640 group). PMID 33693494 ↗

Publications

• Lin Y, Chen X, Ding H, Ye P, Gu J, Wang X, Jiang Z, Li D, Wang Z, Long W, Li Z, Jiang G, Li X, Bi L, Jiang L, Wu J, Guo L, Cai X, Lu X, Chen Q, Chen H, Peng A, Zuo X, Ning R, Zhang Z, Tai Y, Zhang T, Bao C. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology (Oxford). 2021 Nov 3;60(11):5089-5097. doi: 10.1093/rheumatology/keab198.

Drugs

Indications

No indication recorded.